{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:15:29Z","timestamp":1776334529719,"version":"3.51.2"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cpcardiol.2023.101741","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T01:55:15Z","timestamp":1681264515000},"page":"101741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gene Editing as the Future of Cardiac Amyloidosis Therapeutics"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0345-3876","authenticated-orcid":false,"given":"Yashendra","family":"Sethi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Umesh","family":"Mahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimrat","family":"Khehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderbir","family":"Padda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha Annie","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurnaaz","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oroshay","family":"Kaiwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Saith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurpreet","family":"Johal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101741_bib0001","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clin Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101741_bib0002","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.amjmed.2020.06.031","article-title":"Low prevalence of clinically apparent cardiac amyloidosis among carriers of transthyretin V122I variant in a large electronic medical record","volume":"134","author":"Agbor-Etang","year":"2021","journal-title":"Am J Med"},{"issue":"22","key":"10.1016\/j.cpcardiol.2023.101741_bib0003","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101741_bib0004","doi-asserted-by":"crossref","first-page":"I131","DOI":"10.1093\/eurheartjsupp\/suac104","article-title":"The treatment of amyloidosis is being refined","volume":"24","author":"Cantone","year":"2022","journal-title":"Eur Heart J Suppl"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.101741_bib0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.cpcardiol.2023.101741_bib0006","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.101741_bib0007","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.101741_bib0008","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101741_bib0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14797\/mdcvj.1050","article-title":"Cardiac amyloidosis treatment","volume":"18","author":"Stern","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.101741_bib0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101741_bib0011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1534\/genetics.110.120717","article-title":"Targeting DNA double-strand breaks with TAL effector nucleases","volume":"186","author":"Christian","year":"2010","journal-title":"Genetics"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101741_bib0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"16","key":"10.1016\/j.cpcardiol.2023.101741_bib0013","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1093\/nar\/gkp548","article-title":"Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease","volume":"37","author":"Grizot","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"37","key":"10.1016\/j.cpcardiol.2023.101741_bib0014","doi-asserted-by":"crossref","first-page":"13781","DOI":"10.1073\/pnas.0806976105","article-title":"Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors","volume":"105","author":"Suzuki","year":"2008","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.101741_bib0015","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/mt.2010.55","article-title":"Engineering of human pluripotent stem cells by AAV-mediated gene targeting","volume":"18","author":"Khan","year":"2010","journal-title":"Mol Ther"},{"issue":"6121","key":"10.1016\/j.cpcardiol.2023.101741_bib0016","first-page":"819","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science (1979)"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.101741_bib0017","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cpcardiol.2023.101741_bib0018","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.101741_bib0019","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.2507","article-title":"Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease","volume":"31","author":"Cho","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.101741_bib0020","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-Guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"issue":"7587","key":"10.1016\/j.cpcardiol.2023.101741_bib0021","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.101741_bib0022","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering","volume":"153","author":"Wang","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.101741_bib0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/ATVBAHA.117.309326","article-title":"CRISPR-Cas9 genome editing for treatment of atherogenic dyslipidemia","volume":"38","author":"Chadwick","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.101741_bib0024","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nmeth.2681","article-title":"Orthogonal Cas9 proteins for RNA-guided gene regulation and editing","volume":"10","author":"Esvelt","year":"2013","journal-title":"Nat Methods"},{"issue":"7561","key":"10.1016\/j.cpcardiol.2023.101741_bib0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature14592","article-title":"Engineered CRISPR-Cas9 nucleases with altered PAM specificities","volume":"523","author":"Kleinstiver","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.101741_bib0026","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.101741_bib0027","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nbt.2808","article-title":"Improving CRISPR-Cas nuclease specificity using truncated guide RNAs","volume":"32","author":"Fu","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.101741_bib0028","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nbt.2501","article-title":"Efficient genome editing in zebrafish using a CRISPR-Cas system","volume":"31","author":"Hwang","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.101741_bib0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat Commun"},{"issue":"39","key":"10.1016\/j.cpcardiol.2023.101741_bib0030","doi-asserted-by":"crossref","first-page":"15644","DOI":"10.1073\/pnas.1313587110","article-title":"Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis","volume":"110","author":"Hou","year":"2013","journal-title":"Proc Natl Acad Sci"},{"issue":"7546","key":"10.1016\/j.cpcardiol.2023.101741_bib0031","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"issue":"6121","key":"10.1016\/j.cpcardiol.2023.101741_bib0032","first-page":"823","article-title":"RNA-Guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science (1979)"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.101741_bib0033","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nbt.2908","article-title":"Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing","volume":"32","author":"Tsai","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.101741_bib0034","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nbt.2909","article-title":"Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification","volume":"32","author":"Guilinger","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"6268","key":"10.1016\/j.cpcardiol.2023.101741_bib0035","first-page":"84","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science (1979)"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.101741_bib0036","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.cpcardiol.2023.101741_bib0037","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.cpcardiol.2023.101741_bib0038","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target Effects in CRISPR\/Cas9-mediated Genome Engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.101741_bib0039","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.101741_bib0040","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.cpcardiol.2023.101741_bib0041","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21775\/cimb.026.103","article-title":"Ethical Issues Regarding CRISPR Mediated Genome Editing","volume":"26","author":"Shinwari","year":"2018","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.cpcardiol.2023.101741_bib0042","unstructured":"Intellia Therapeutics, ClinicalTrials.gov Identifier: NCT04601051. Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM). 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04601051?term=CRISPR&cond=Cardiac+Amyloidosis&draw=2&rank=1."},{"issue":"02","key":"10.1016\/j.cpcardiol.2023.101741_bib0043","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9627.1000266","article-title":"Ethical Issues in Genome Editing using Crispr\/Cas9 System","volume":"07","author":"E","year":"2016","journal-title":"J Clin Res Bioeth"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.101741_bib0044","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s42466-021-00155-8","article-title":"Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis","volume":"3","author":"Dohrn","year":"2021","journal-title":"Neurol Res Pract"},{"issue":"9","key":"10.1016\/j.cpcardiol.2023.101741_bib0045","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2023.101741_bib0046","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101741_bib0047","unstructured":"Wood K PMSJ. Development of NTLA-2001, a CRISPR\/Cas9 genome editing therapeutic for the treatment of ATTR. 2023 https:\/\/www.intelliatx.com\/wp-content\/uploads\/development-of-ntla-2001.pdf."},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.101741_bib0048","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41588-020-0623-4","article-title":"Cas9 activates the p53 pathway and selects for p53-inactivating mutations","volume":"52","author":"Enache","year":"2020","journal-title":"Nat Genet"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623001585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623001585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:16:49Z","timestamp":1758939409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623001585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0146280623001585"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101741","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Editing as the Future of Cardiac Amyloidosis Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101741"}}